Nyxoah (NASDAQ:NYXH) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Nyxoah (NASDAQ:NYXH) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $16.00 price objective on the stock.

Several other research analysts have also recently issued reports on the company. HC Wainwright dropped their price target on Nyxoah from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, October 11th. Oppenheimer cut their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $17.00.

Nyxoah Price Performance

Shares of Nyxoah stock opened at $9.49 on Tuesday. Nyxoah has a 52 week low of $4.00 and a 52 week high of $20.00. The company has a current ratio of 5.47, a quick ratio of 5.16 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $8.97 and its two-hundred day moving average price is $8.81.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.01). Nyxoah had a negative return on equity of 56.39% and a negative net margin of 1,061.31%. The business had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.93 million. Equities research analysts expect that Nyxoah will post -1.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

A number of institutional investors have recently bought and sold shares of the business. Kovack Advisors Inc. purchased a new stake in Nyxoah in the 3rd quarter worth approximately $96,000. CVI Holdings LLC acquired a new stake in Nyxoah during the second quarter valued at $1,292,000. Ikarian Capital LLC purchased a new position in Nyxoah in the first quarter valued at about $684,000. Finally, Iron Triangle Partners LP acquired a new position in Nyxoah in the 1st quarter worth about $3,413,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.